Collateral to begin Phase IIb/III

CLTX and partner Schering (SHR) will begin shortly double-blind, placebo-controlled Phase IIb/III trials in the U.S. and Europe of Ad5FGF4 gene therapy to treat patients with stable exertional angina ...